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Abstract
Background: Generalised Anxiety Disorder (GAD) is a highly prevalent psychiatric disorder. Effective prevention in
young adulthood has the potential to reduce the prevalence of the disorder, to reduce disability and lower the
costs of the disorder to the community. The present trial (the WebGAD trial) aims to evaluate the effectiveness of
an evidence-based online prevention website for GAD.
Methods/Design: The principal clinical question under investigation is the effectiveness of an online GAD
intervention (E-couch) using a community-based sample. We examine whether the effect of the intervention can
be maximised by either human support, in the form of telephone calls, or by automated support through emails.
The primary outcome will be a reduction in symptoms on the GAD-7 in the active arms relative to the non active
intervention arms.
Discussion: The WebGAD trial will be the first to evaluate the use of an internet-based cognitive behavioural
therapy (CBT) program contrasted with a credible control condition for the prevention of GAD and the first formal
RCT evaluation of a web-based program for GAD using community recruitment. In general, internet-based CBT
programs have been shown to be effective for the treatment of other anxiety disorders such as Post Traumatic
Stress Disorder, Social Phobia, Panic Disorder and stress in clinical trials; however there is no evidence for the use
of internet CBT in the prevention of GAD. Given the severe shortage of therapists identified in Australia and
overseas, and the low rates of treatment seeking in those with a mental illness, the successful implementation of
this protocol has important practical outcomes. If found to be effective, WebGAD will provide those experiencing
GAD with an easily accessible, free, evidence-based prevention tool which can be promoted and disseminated
immediately.
Trial Registration: Controlled-trials.com: ISRCTN76298775
Background
Generalised Anxiety Disorder (GAD) is a disabling men-
tal illness. Approximately 5% of the general population
experiences the disorder at least once in their lifetime
[1], with populations surveys indicating a lifetime preva-
lence rate of between 4.3-5.9% and a 12 month
prevalence rate of between 1.2-1.9% [2,3]. Although little
data is available, best estimates suggest that the annual
incidence rate for GAD is 1.8% [see [4]].
GAD is characterised by prolonged excessive worry
within numerous domains, restlessness, fatigue, difficulty
concentrating, irritability, muscle tension, and sleep dis-
turbance [5]. It can be highly debilitating and has a sig-
nificant burden on the community largely due to low
rates of treatment sought as well as a shortage of thera-
pists identified in Australia and around the world [6].
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Data from the US National Comorbidity Survey indi-
cates that only approximately 37% of those surveyed
reported seeking treatment services for GAD [7]. Sub-
threshold anxiety (i.e., elevated symptom levels which
fall short of criteria for clinical diagnosis) is also com-
mon with a prevalence of 3.6% in the population. It is
also associated with suicide attempts, and work impair-
ment, and has not been found to differ substantially in
profile from clinical GAD [8].
The cost of GAD to the community is elevated as a
result of its chronic course [9]. GAD frequently presents
early in the lifespan and affects the individual through-
out adulthood, with an estimated lag time to treatment
of between 9 and 23 years [10]. Consequently, effective
prevention in young adulthood has the ability to reduce
ongoing disability and costs to the community [11,12].
There is some evidence that GAD can be prevented
either through a focus on salient risk factors such as
anxiety sensitivity [13], pessimistic thinking [14], family
history [15], withdrawn or inhibited temperament [16],
known as selective prevention programs [17], or by tar-
geting sub-threshold symptoms in those who do not
meet diagnostic criteria for the disorder (indicated pre-
vention programs) [18]. However, very few programs
with a genuine preventive focus have been conducted
with young adults, and rarely have prevention programs
investigated the reduction in the number of incident
cases. According to the Institute of Medicine (IOM) cri-
teria [19], true prevention trials are those that exclude
individuals meeting criteria for the disorder. In adults,
there are only two such trials [14,17] and no indicated
trials, although one targeting the very elderly is currently
in progress [20]. Trial data from school programs com-
bined with other prevention studies indicates that pre-
vention rates vary, depending on the recruitment and
prevention strategy, intervention type, length of follow-
up or sample age. Findings from these studies indicate
that the percentage of participants without intervention
meeting diagnostic criteria at follow-up are higher
(8-54%) than those exposed to prevention programs
(1-20%). However, these trials to date provide a scant
evidence base on which to build practical prevention
programs for adults or to provide unequivocal evidence
for the benefit of prevention programs outside of school
environments. A definitive prevention trial in young
adults is needed. A trial of this sort provides the oppor-
tunity to establish the benefit of prevention, and also to
increase knowledge about the etiological factors that
predict conversion to GAD.
The study protocol presented here provides a descrip-
tion of the background to the WebGAD trial including
a description of: 1) the benefits of web-based interven-
tions; 2) the effectiveness of web-based interventions
for mental disorders; and 3) the nature of attrition.
A description of the methods, design, and current status
of the trial is also included as is a discussion of the pos-
sible implications that may arise from the findings.
Benefits of Web-based Interventions
Web interventions have distinct advantages with respect
to prevention where easily implemented, cost effective,
high volume interventions are needed simultaneously by
large numbers of individuals. Evidence suggests that
web-based interventions are often preferentially sought
for the anonymity, their lack of face-to-face contact, and
their capacity to be used privately at home [21]. They
may ‘increase participation likelihood among individuals
who might not otherwise seek care’ [22]. Internet inter-
ventions - if automated - are able to deliver psychiatric
intervention with fidelity, giving them an advantage over
other programs. The use of the internet in health has
high acceptability, with over 38% of Americans reporting
that the internet has helped the way they take care of
their health [23]. This trend strongly indicates that peo-
ple are increasingly taking a central role in the manage-
ment of their own health and evidence suggests that
self-help techniques are effective in the treatment of
mental disorders [24]. In addition, it has been reported
that people are increasingly turning to the internet for
information specifically on mental health [25].
Effectiveness of Web-based Interventions for Mental
Disorders
There is evidence that web based interventions (often in
combination with therapist input) are effective for a
range of mental health symptoms including depression
[26,27], panic [28,29], post traumatic stress disorder
(PTSD) [30], perceived stress in schizophrenia [31],
stress [32], insomnia [33], and eating disorders [34,35].
As noted above, the effectiveness of these applications
for the prevention of GAD has not been evaluated.
Attrition
An important challenge for web-based interventions is
the high rate of attrition. Evidence [35] suggests that
attrition rates for web-based programs are quite high. A
number of factors have been identified that can improve
adherence to e-health programs, including push factors,
or ‘tracking’, which include reminders to visit or return
to websites, and personal contact through face-to-face
or phone contact with service providers or trial
researchers. Rewards or enhancements for engagement
with the site or service, and endorsement and feedback
by professional health care providers have also been
found to increase retention rates [36]. Comparison of
the outcomes of two trials of a depression website sug-
gested that support (weekly telephone follow-up with
instructions to visit the website) resulted in substantially
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higher module use than the same intervention without
such contact [37]. Trials of another ‘overcoming depres-
sion’ website reported that reminders (telephone and
email) were likely to be the crucial factor in determining
retention (and improvement) [26]. However, overall,
there has been little systematic investigation of factors
which promote adherence in a range of mental health
conditions. For this reason, there is a clear need to
examine whether web interventions are enhanced by
support. Thus, the WebGAD study will investigate the
effect of telephone and email reminders versus no con-
tact on retention rates.
Prevention condition: “E-couch”
In the absence of research indicating reliable risk factors
for the onset of anxiety, and given that our sample was
selected on the basis of symptoms, our approach for this
trial is to offer a preventative program that included
components found effective for both the treatment of
GAD, and in the prevention of GAD. As noted above,
data from prevention trials are relatively weak, given the
small number of completed trials. The intervention, E-
couch, will be delivered as a 10-week multimedia inter-
net application. The E-couch program is comprised of
four sections - psycho-education, CBT, relaxation and
exercise. Research indicates that all four components are
effective in reducing anxiety levels [34,38].
Psycho-education will be covered in weeks 1 and 2. It
contains information about the definition of worry; its
distinction from stress and fear; the differentiation of
GAD from Panic Disorder, Specific Phobia, Separation
Anxiety Disorder, Adjustment Disorder, and PTSD; pre-
valence rates; the problem of comorbidity and informa-
tion on medical, psychological, and lifestyle treatments
for anxiety. The psycho-education section is modelled
on mental health literacy interventions that have been
shown to improve attitudes to and reduce symptoms of
depression and anxiety [27]. It is based on clinical prac-
tice guidelines [39] as well as on reviews of evidence of
alternative and lifestyle treatments [34]. The Cognitive
Behaviour Therapy (CBT) toolkits will be introduced in
weeks 3, 4, 5, 6, and 7. The CBT toolkits are designed
to address typical anxious thoughts and targets worry-
related thoughts and beliefs [40]. The CBT component
for anxiety is based on previously developed materials
which have established efficacy for anxiety cognitions
and beliefs in at-risk individuals [13,41]. The third sec-
tion of the E-couch intervention provides two Relaxa-
tion Exercises. These will be downloadable from the site
during weeks 8 and 9 of the intervention, although they
are freely available at any time. Mindful Meditation is a
type of meditation which involves using awareness of
breathing to keep a focus on the present moment. The
Progressive Muscle Relaxation (PMR) component, aims
to induce a relaxation response through systematic
relaxation of the body. It involves participants progres-
sively tensing and relaxing each muscle in their body,
whilst also paying close attention to feelings of tension
and relaxation. The Physical Activity intervention intro-
duced in week 10 but lasting for longer than a week,
uses walking, tailored to stages of change in participants’
level of fitness.
Attention Control Condition: “HealthWatch”
HealthWatch is an online program first developed for
the ANU WellBeing Study [42]. In the form employed
in the current study it provides information about var-
ious health topics each week for 10 weeks. These cover
environmental health, nutrition myths, heart health,
activity, medication, the effects of temperature, oral
health, blood pressure and cholesterol, calcium, and
back pain. To encourage interaction, participants are
also asked to respond to a number of questions about
potential risk factors for anxiety. Preliminary evidence
from the WellBeing research trial suggests that the site
is not associated with a reduction in depressive or anxi-
ety symptoms over time.
Participants in the HealthWatch or E-couch condi-
tions will complete the 10 week online program at their
own leisure at home or office. Each module will last
between 30 and 60 minutes and will be deployed weekly.
If participants in the E-couch condition wish to con-
tinue using the program after the intervention period,
they have the option of accessing it through the open-
access website.
Methods/Design
Design of the WebGAD Trial
The study is designed as a five arm randomised con-
trolled trial with three active interventions and two
comparators. There will be five measurement occasions:
screening, baseline, post-test, and follow-ups at 6 and 12
months after the post-test survey. This study was
granted ethical approval by the Australian National Uni-
versity Human Research Ethics Committee (protocol
number 2008/548). If approved by our ethics committee,
an additional 2 year follow-up period will be included.
Scales that will be administered at each time point are
listed below in Table 1.
Recruitment & Inclusion/Exclusion Criteria
Recruitment will take place in two steps. Step 1 will
involve a screening assessment, mailed to individuals
aged 18-30 years randomly selected from the Australian
Electoral Roll. In Australia, it is compulsory for all Aus-
tralian citizens aged 18 years or older to be registered
on the Commonwealth Electoral Roll. Randomly
selected individuals will be screened for symptoms using
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the GAD-7 [43] and individuals with GAD-7 scores 5 or
greater will progress to step 2.
Step 2 will involve the administration of the MINI
diagnostic interview [44] to exclude individuals with a
diagnosis of current GAD (and other relevant diag-
noses). Diagnoses based on the MINI will result in refer-
ral. Participants ineligible to take part in the prevention
trial due to a positive GAD diagnosis will be offered the
opportunity to take part in the WebGAD Treatment
trial being conducted by the Brain & Mind Research
Institute at the University of Sydney (ISRCTN76298775)
(Christensen, Guastella, Mackinnon, Griffiths, Eagleson,
Batterham, Kalia, Kenardy, Bennett, & Hickie: Protocol
for a randomised controlled trial investigating the effec-
tiveness of an online e-health application compared to
attention placebo or sertraline in the treatment of gen-
eralised anxiety disorder, Submitted). A complete list of
inclusion/exclusion criteria can be found in Table 2.
The study will aim to recruit a total of 600 participants
(120 for each of the trial arms). Recruitment will be car-
ried out in four intake cohorts over 12-18 months.
Since depression and anxiety are substantially corre-
lated, depression is not an exclusion criterion for the
trial, nor is personality disorder. However, participants
who meet criteria for Panic Disorder, Social Phobia or
PTSD will be excluded and offered treatment through
the clinic at the Brain & Mind Research Institute.
Components of the Five Trial Arms
The Prevention arm of the WebGAD study consists of
five experimental conditions. Three of these involve the
provision of the active intervention, E-couch. The two
HealthWatch control conditions serve as attention and
assessment matched credible comparator/placebo inter-
ventions. E-couch will be delivered as a 10-week web
intervention with minimal contact. It will be delivered
either a) on its own, with no telephone or email remin-
ders, or b) with weekly automated emails serving as
Table 1 Scales to be administered at each measurement occasion
Screening Baseline Post-test 6 month 12 month
Demographics X
GAD-7 X X X X X
Prototypes X X
Generalised Anxiety Stigma Scale X X X
Self-perceived emotional health X X
Social Phobia Inventory X X X
Patient Health Questionnaire Panic X X X
Patient Health Questionnaire Depression X X X X
Kessler 10 X X X
Panic & Social phobia screeners X X X
Anxiety Literacy Scale X X X X
Eligibility X
Anxiety Sensitivity Index X X X X
Penn State Worry Questionnaire X X X X
Centre for Epidemiological Studies Depression X X X X
Days out of role X X X X
Perceived helpfulness of sources X X X X
Help seeking X X X X
Medical Outcomes Study Social Support Survey X
Childhood adversity X
Life events X
Alcohol Use Disorders Identification Test X X X X
Physical health X X X X
Medications X X X X
Smoking X X X X
Beliefs about internet X X X
Usefulness of E-couch X X X
Condition preference X
Contamination X X
Employment status items (in demographics) X
Note: For details of the references for these measures please see below.
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reminders and containing supportive messages, or c)
with weekly telephone calls, which prov—ide supportive
messages and reminders. The control condition, Health-
Watch, matched for participant involvement will be
delivered either d) alone with no reminders or phone
calls, or e) in conjunction with weekly telephone calls.
A comparison of outcomes under conditions (a) and
(d) will establish the basic effectiveness of the interven-
tion. The remaining conditions will test whether the
effectiveness of the E-couch program can be enhanced
with support, and if so, what kind of support. Condi-
tions (c) and (e) can determine whether any prevention
benefit found is attributable to the contact and support
offered through telephone calls or to the intervention
itself. The email condition, (b), will establish the effec-
tiveness of automated support. This has critical imple-
mentation implications because automated internet
applications are cheap and easy to disseminate.
Study Hypotheses
• It is hypothesised that E-couch online therapy,
compared with the attention control condition, will
reduce symptoms of anxiety, prevent the develop-
ment of GAD, reduce worry, and depression,
improve mental health literacy, enhance help seeking
and improve other secondary outcomes.
• The addition of support for participants under-
going E-couch therapy, either in the form of auto-
mated emails or telephone calls, is expected to have
a greater impact on participants’ anxiety levels than
E-couch alone.
• E-couch therapy plus weekly telephone support
will have greater effect than weekly telephone sup-
port in the context of the control condition.
• In terms of support, E-couch plus weekly tele-
phone support will not be significantly inferior to E-
couch plus weekly email support, i.e., that these two
forms of support will not, effectively, differ in their
effectiveness.
• It is also hypothesized that lower initial symptoms,
fewer past treatment episodes, fewer intimate
relationships, lower education, poorer computer lit-
eracy and lower perceived need for treatment will
predict increased drop out and reduced adherence.
Primary Outcome Measure
The primary outcome is the severity of anxiety symp-
toms, assessed using the GAD-7 scale [43].
Secondary Outcome Measures
Secondary outcomes include: GAD caseness status at six
months post-intervention, as measured by a second
administration of the MINI; worry, measured by the
Penn State Worry Questionnaire [45]; anxiety sensitivity,
as measured by ASI [46]; depression symptoms assessed
by the CES-D [47] and PHQ Depression [48]; harmful/
hazardous alcohol use as measured by AUDIT [49]; dis-
ability, measured by the ‘Days Out of Role’ questions
from the US National Comorbidity Survey and number
of hours worked per day [50]; health knowledge using
formats previously developed for depression and adapted
for anxiety; psychological distress using the K10 [51];
help seeking using scales measuring actions taken to
overcome anxiety adapted from parallel depression ver-
sions of these [52]. In addition, changes in perceived
need for treatment will be assessed by the following
item: “Was there ever a time in the last 12 months
when you felt that you might need to see a health pro-
fessional because of problems with your emotions or
nerves?” [53].
The following measures will be included to assess out-
come predictors and potential mediators of the effective-
ness of the intervention. Personal and perceived stigma
toward those with GAD will be assessed by a new scale
currently under development - the Generalised Anxiety
Stigma Scale, symptoms of social phobia will be assessed
using the Social Phobia Inventory [54] and a new social
phobia screener that is in development, whilst symp-
toms of panic will be measured using PHQ Panic [55]
and a new panic disorder screener that is in develop-
ment. Availability of social support will be assessed
Table 2 Inclusion/Exclusion Criteria for WebGAD Prevention Trial.
Inclusion Criteria Exclusion Criteria
18-30 years old Currently undergoing CBT or seeing a psychologist/psychiatrist
Score ≥ 5 on the GAD-7 scale Current or previous diagnosis of Bipolar Disorder, Schizophrenia, or Psychosis
Consent to participate in the study At risk of self-harm or suicide based on the MINI depression module
Do not meet criteria for GAD on MINI GAD
module
Current diagnosis of panic disorder, social phobia or post-traumatic stress disorder according to
MINI criteria
Provide an active email address and phone
number
Currently on psychiatric medications
Sufficient English language literacy
Access to the internet (home or work)
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using MOS Social Support Survey and adherence mea-
sured by survey return rates and website usage. Prefer-
ences for treatment type and expectations of the trial
will be assessed using previously developed formats [27].
Predictors of outcome including smoking, medication
use, perceived helpfulness of sources, childhood adver-
sity, physical health and life events will use scales devel-
oped for the PATH through Life Study [56].
Subsidiary Outcome Measures
Subsidiary outcomes will be measured. These will
include direct costs of each arm to determine the merit
of online treatments, satisfaction using previously used
self report scales, and reason for drop out which will be
assessed using a modified Ritterband’s Adherence Inter-
view [57]. In addition, the demographic data reported in
the screening phase will be analysed to compare those
who responded to the general population.
Sample Size and Power Calculations
Most treatment trials of CBT based GAD report an
effect of approximately .6 SDs relative to placebo and .8
SDs relative to minimal contact [58]. For prevention in
adults, Kenardy and colleagues [13,41] reported an effect
size change of approximately .6 relative to control con-
dition for cognitions and depression. However, because
the same test was used to both select the sample and
measure outcome, there may have been regression to
the mean, which may have inflated this effect. For the
purposes of the present trial, we assume a correlation of
.7 between pre- and post-test measurements, and find
that the study will have 80% power to detect differences
in change from baseline of approximately .3 standard
deviations in a priori contrasts of trial arms conducted
within the framework of an omnibus test of condition
by time mixed model repeated measures analysis.
Comparison of email to human support will be under-
taken within a non-inferiority/equivalence framework
[59]. This will maximize power to detect a statistically
significant inferiority of email to human support. For
the evaluation of prevention-significant change, there
will be 80% power to detect a relative advantage as low
as 25% to 60% in the response rate in the prevention
compared to placebo depending on baseline response.
Greater power may be able to be obtained by including
all trial arms (a, b, c) and placebo arms (d, e) in this
analysis. Power to detect differences in risk rates for
diagnosis of incident GAD is constrained by the large
sample required and the time period over which partici-
pants will be followed. Nevertheless, incidence rates will
be calculated and compared using methods established
as being accurate for low rates in moderate sized sam-
ples [60]. Other categorical analyses (relative risk reduc-
tion, number needed to treat) will be based on the
criteria of 20% reduction in symptoms and absence of
DSM GAD caseness. This sample size will allow for
multivariate analyses with up to six predictors, assuming
moderate size effects [61]. In this trial we estimate pre-
post effect sizes for Conditions 1-5 to be .5, .15, .8, .2
and .8 SDs, respectively. Differences between active and
comparator arms will be detected within this trial with
good power, as outlined above. With regard to the
examination of factors associated with response, adher-
ence and drop out, allowing for 15% attrition, the study
will have 80% power to detect simple associations
between variables just below r = 0.3. When predictors
are dichotomous, there will be similar power to detect
differences just less than 0.6 standard deviations in
response between groups.
Random Allocation Procedure
As required by ICH Guideline E9 [62], randomisation of
participants to treatment groups will be carried out
under trial biostatisticians who will not be involved in
the day to day conduct of the trial. Random allocation
to the treatment groups will occur immediately after the
baseline interview has been completed. The algorithm
for random allocation will consist of a stratified block
design, with stratification by level of symptoms, gender,
and past diagnosis of GAD and a block size of 10.
There will be eight strata (2 × 2 × 2), corresponding to
higher/lower symptom level, female/male gender, and
previous diagnosis of GAD. Allocation will be adminis-
tered within the existing software architecture developed
by the investigators. Participants will be informed that
they have been assigned to a condition after completing
the baseline interview, and may begin the first module
one week later.
Statistical Considerations
The senior trial biostatistician will be blinded to the
treatment groups being analysed until the analysis has
been completed, rendering the statistical analysis
masked. Furthermore, no trial biostatisticians will be
involved in the allocation of individuals to inventions,
administration of treatment, measuring outcomes, enter-
ing data, or assessing eligibility of participants.
Primary analyses [43] will be undertaken on an intent-
to-treat (ITT) basis, including all participants randomised
regardless of treatment actually received or withdrawal
from the trial. Mixed-model repeated measures
(MMRM) analyses will be used because of the ability of
this approach to include participants with missing data
without using discredited techniques such as last obser-
vation carried forward [63]. For non-inferiority compo-
nents, appropriate analyses will be undertaken. These
will generally not be ITT based, as this model is often
anti-conservative in these circumstances [56].
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Non-linear mixed models will be used to analyse cate-
gorical outcomes including increased caseness status
and whether the participant has met the benchmark
decrease of 20% from baseline at each of the follow-up
assessments on the GAD-7. If necessary, multiple impu-
tation including demographic and other background
variables as predictors will be used to allow inclusion of
data from all participants and not simply those with
data which would permits inclusion in mixed models.
Additional analyses will explore participant characteris-
tics which moderate outcome and, if appropriate, levels
of presenting severity associated with significant
improvement. Other outcomes (such as data on reasons
for dropout) will be described.
Discussion
The WebGAD trial represents an opportunity to test the
potential benefit of a population-based preventive inter-
vention for a mental disorder in adults. This will be the
first true prevention trial of an indicated GAD prevention
intervention in young adults. It will be the first Internet
trial for any mental disorder that simultaneously investi-
gates the role of human and automated support and
which goes beyond research directed at effectiveness–
although this is also a goal–to research focusing on pro-
cess variables, such as predictors of adherence and of
non-response. It will determine direct costs and out-
comes with direct relevance to implementation. The
large target sample size will permit the development of
exploratory predictive models and may enable targeting
of modifiable causes of non-response. The E-couch pro-
gram has been developed on a platform that is immedi-
ately scalable, thus making it a practical prevention
program. If effective, E-couch could be promoted and
disseminated immediately to the population as a whole.
Status of the Trial
The study will commence in April 2010. To allow suffi-
cient time to implement the intervention, the sample
will be recruited in four intake cohorts conducted 2-3
months apart, with the pilot study beginning in June
2010, the second intake cohort beginning in August
2010, in the third intake cohort in October 2010, and
the last intake cohort in December 2010. The trial is
expected to end in June 2012.
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